You just read:

Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II

News provided by

Sangamo BioSciences, Inc.

20 Jun, 2016, 07:00 ET